176 related articles for article (PubMed ID: 26928373)
21. Adverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate tight control therapy: the CAMERA study.
Verstappen SM; Bakker MF; Heurkens AH; van der Veen MJ; Kruize AA; Geurts MA; Bijlsma JW; Jacobs JW;
Ann Rheum Dis; 2010 Jun; 69(6):1044-8. PubMed ID: 19581281
[TBL] [Abstract][Full Text] [Related]
22. Methotrexate treatment in rheumatoid arthritis and elevated liver enzymes: A long-term follow-up of predictors, surveillance, and outcome in clinical practice.
Karlsson Sundbaum J; Eriksson N; Hallberg P; Lehto N; Wadelius M; Baecklund E
Int J Rheum Dis; 2019 Jul; 22(7):1226-1232. PubMed ID: 31012257
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of leflunomide 100mg weekly compared to low dose methotrexate in patients with active rheumatoid arthritis. Double blind, randomized clinical trial.
Jaimes-Hernández J; Meléndez-Mercado CI; Mendoza-Fuentes A; Aranda-Pereira P; Castañeda-Hernández G
Reumatol Clin; 2012; 8(5):243-9. PubMed ID: 22763150
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of liver fibrosis by transient elastography in methotrexate treated patients.
Barbero-Villares A; Mendoza J; Trapero-Marugan M; Gonzalez-Alvaro I; Daudén E; Gisbert JP; Moreno-Otero R
Med Clin (Barc); 2011 Nov; 137(14):637-9. PubMed ID: 21719043
[TBL] [Abstract][Full Text] [Related]
25. Long-term use of methotrexate does not result in hepatitis B reactivation in rheumatologic patients.
Laohapand C; Arromdee E; Tanwandee T
Hepatol Int; 2015 Apr; 9(2):202-8. PubMed ID: 25788188
[TBL] [Abstract][Full Text] [Related]
26. Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated.
Atallah E; Grove JI; Crooks C; Burden-Teh E; Abhishek A; Moreea S; Jordan KM; Ala A; Hutchinson D; Aspinall RJ; Murphy R; Aithal GP
J Hepatol; 2023 May; 78(5):989-997. PubMed ID: 36702175
[TBL] [Abstract][Full Text] [Related]
27. The effect of long-term methotrexate therapy on hepatic fibrosis in rheumatoid arthritis.
Bjorkman DJ; Boschert M; Tolman KG; Clegg DO; Ward JR
Arthritis Rheum; 1993 Dec; 36(12):1697-701. PubMed ID: 8250989
[TBL] [Abstract][Full Text] [Related]
28. Hepatic and hematological adverse effects of long-term low-dose methotrexate therapy in rheumatoid arthritis: An observational study.
Dubey L; Chatterjee S; Ghosh A
Indian J Pharmacol; 2016; 48(5):591-594. PubMed ID: 27721549
[TBL] [Abstract][Full Text] [Related]
29. Prevalence of liver fibrosis by Fibroscan in patients on long-term methotrexate therapy for rheumatoid arthritis.
Bafna P; Sahoo RR; Hazarika K; Manoj M; Rungta S; Wakhlu A
Clin Rheumatol; 2021 Sep; 40(9):3605-3613. PubMed ID: 33686476
[TBL] [Abstract][Full Text] [Related]
30. Clinical liver disease in patients with rheumatoid arthritis taking methotrexate.
Phillips CA; Cera PJ; Mangan TF; Newman ED
J Rheumatol; 1992 Feb; 19(2):229-33. PubMed ID: 1629819
[TBL] [Abstract][Full Text] [Related]
31. Risk factors for methotrexate-induced abnormal laboratory monitoring results in patients with rheumatoid arthritis.
Kent PD; Luthra HS; Michet C
J Rheumatol; 2004 Sep; 31(9):1727-31. PubMed ID: 15338491
[TBL] [Abstract][Full Text] [Related]
32. Significance of liver biopsy for the evaluation of methotrexate-induced liver damage in patients with rheumatoid arthritis.
Osuga T; Ikura Y; Kadota C; Hirano S; Iwai Y; Hayakumo T
Int J Clin Exp Pathol; 2015; 8(2):1961-6. PubMed ID: 25973089
[TBL] [Abstract][Full Text] [Related]
33. Histopathologic findings in the liver of rheumatoid arthritis patients treated with long-term bolus methotrexate.
Aponte J; Petrelli M
Arthritis Rheum; 1988 Dec; 31(12):1457-64. PubMed ID: 3196364
[TBL] [Abstract][Full Text] [Related]
34. Methotrexate: long-term safety and efficacy in an Australian consultant rheumatology practice.
Varatharajan N; Lim IG; Anandacoomarasamy A; Russo R; Byth K; Spencer DG; Manolios N; Howe GB
Intern Med J; 2009 Apr; 39(4):228-36. PubMed ID: 19402861
[TBL] [Abstract][Full Text] [Related]
35. Risk factors associated with the cumulative survival of low-dose methotrexate in 273 Japanese patients with rheumatoid arthritis.
Ideguchi H; Ohno S; Ishigatsubo Y
J Clin Rheumatol; 2007 Apr; 13(2):73-8. PubMed ID: 17414533
[TBL] [Abstract][Full Text] [Related]
36. Methotrexate-associated primary hepatic lymphoma and cranial neuropathy in a patient with rheumatoid arthritis: A case report with clinical follow-up over a 7-year period.
Park JE; Lee KM; Choi HY; Ahn SE; You MW
Medicine (Baltimore); 2019 Apr; 98(17):e14997. PubMed ID: 31027052
[TBL] [Abstract][Full Text] [Related]
37. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis.
Shea B; Swinden MV; Tanjong Ghogomu E; Ortiz Z; Katchamart W; Rader T; Bombardier C; Wells GA; Tugwell P
Cochrane Database Syst Rev; 2013 May; 2013(5):CD000951. PubMed ID: 23728635
[TBL] [Abstract][Full Text] [Related]
38. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research.
Salliot C; van der Heijde D
Ann Rheum Dis; 2009 Jul; 68(7):1100-4. PubMed ID: 19060002
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort.
Müller RB; von Kempis J; Haile SR; Schiff MH
Semin Arthritis Rheum; 2015 Aug; 45(1):28-34. PubMed ID: 25895697
[TBL] [Abstract][Full Text] [Related]
40. Hepatoprotective effect of tumour necrosis factor alpha blockade in psoriatic arthritis: a cross-sectional study.
Seitz M; Reichenbach S; Möller B; Zwahlen M; Villiger PM; Dufour JF
Ann Rheum Dis; 2010 Jun; 69(6):1148-50. PubMed ID: 19854710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
